It is increasingly clear that juvenile dermatomyositis (JDM), a rare complex autoimmune disorder that involves autoimmune, vascular and inflammatory mechanisms, is not homogeneous. Rather, the diagnosis of JDM covers a heterogeneous group of patients, with a wide spectrum of outcomes ranging from complete remission through to those with recalcitrant difficult to treat disease, with ongoing active skin rash, calcinosis or vasculopathic complications.
In this talk we will consider novel biomarkers that can distinguish these subphenotypes, and the underlying genetics or mechanistic pathways that may drive these disease types. We will also review methods with which to assess and monitor disease and international efforts to standardize the data and samples that are considered minimal to allow the optimal management of patients with JDM.
Disclosure of Interest None declared